Chimeric form of tumor necrosis factor-α has enhanced surface expression and antitumor activity

Cancer Gene Therapy

Volumn 16, Issue 1, 2009, Pages 53-64

  Rieger, R ^a   Whitacre, D ^a   Cantwell, M J ^a,c   Prussak, C ^b   Kipps, T J ^a,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b MICROFABRICA INC   (United States)

^c Adventrx   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Adenovirus; CD154; Factor; Immunotherapy; Necrosis; Tumor

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CD154 TUMOR NECROSIS FACTOR FUSION; CD70 ANTIGEN; GREEN FLUORESCENT PROTEIN; IMMUNOLOGIC AGENT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER REGRESSION; CARBOXY TERMINAL SEQUENCE; CHIMERA; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION;

ADENOVIRIDAE; ANIMALS; CD40 LIGAND; FEMALE; GENE THERAPY; HELA CELLS; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

ADENOVIRIDAE; MUS;

EID: 57649133257     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.57     Document Type: Article

References (43)

1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666-3670.
2. Spriggs DR, Sherman ML, Frei III E, Kufe DW. Clinical studies with tumour necrosis factor. Ciba Found Symp 1987; 131: 206-227.
3. Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987; 47: 2986-2989.
4. Selby P, Hobbs S, Viner C, Jackson E, Jones A, Newell D et al. Tumour necrosis factor in man: clinical and biological observations. Br J Cancer 1987; 56: 803-808.
5. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-733.
6. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997; 385: 733-736.
7. Decoster E, Vanhaesebroeck B, Vandenabeele P, Grooten J, Fiers W. Generation and biological characterization of membrane-bound, uncleavable murine tumor necrosis factor. J Biol Chem 1995; 270: 18473-18478.
8. Perez C, Albert I, DeFay K, Zachariades N, Gooding L, Kriegler M. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 1990; 63: 251-258.
9. Mueller C, Corazza N, Trachsel-Loseth S, Eugster HP, Bühler-Jungo M, Brunner T et al. Noncleavable transmembrane mouse tumor necrosis factor-alpha (TNFalpha) mediates effects distinct from those of wild-type TNFalpha in vitro and in vivo. J Biol Chem 1999; 274: 38112-38118.
10. Li Q, Li L, Shi W, Jiang X, Xu Y, Gong F et al. Mechanism of action differences in the antitumor effects of transmembrane and secretory tumor necrosis factor-alpha in vitro and in vivo. Cancer Immunol Immunother 2006; 55: 1470-1479.
11. Grell M, Douni E, Wajant H, Löhden M, Clauss M, Maxeiner B et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83: 793-802.
12. Killar L, White J, Black R, Peschon J. Adamalysins. A family of metzincins including TNF-alpha converting enzyme (TACE). Ann NY Acad Sci 1999; 878: 442-452.
13. Mendoza RB, Cantwell MJ, Kipps TJ. Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization. J Immunol 1997; 159: 5777-5781.
14. Flick DA, Gifford GE. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods 1984; 68: 167-175.
15. Pietravalle F, Lecoanet-Henchoz S, Aubry JP, Elson G, Bonnefoy JY, Gauchat JF. Cleavage of membrane-bound CD40 ligand is not required for inducing B cell proliferation and differentiation. Eur J Immunol 1996; 26: 725-728.
16. Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 2003; 4: 565-573.
17. Mocellin S, Rossi CR, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 2005; 16: 35-53.
18. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002; 296: 1634-1635.
19. Ranheim EA, Kipps TJ. Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40 L. Cell Immunol 1995; 161: 226-235.
20. Armitage RJ. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol 1994; 6: 407-413.
21. Ryffel B, Mihatsch MJ. TNF receptor distribution in human tissues. Int Rev Exp Pathol 1993; 34(Part B): 149-156.
22. Vrouenraets BC, Klaase JM, Nieweg OE, Kroon BB. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol 1998; 14: 224-231.
23. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52-60.
24. Vrouenraets BC, Kroon BB, Ogilvie AC, van Geel AN, Nieweg OE, Swaak AJ et al. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 1999; 6: 405-412.
25. Zimmermann VS, Bondanza A, Rovere-Querini P, Colombo B, Sacchi A, Fascio U et al. Characterisation of functional biotinylated TNF-alpha targeted to the membrane of apoptotic melanoma cells. J Immunol Methods 2003; 276: 79-87.
26. Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H et al. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 2003; 63: 3202-3210.
27. Bauer S, Adrian N, Williamson B, Panousis C, Fadle N, Smerd J et al. Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein. J Immunol 2004; 172: 3930-3939.
28. Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003; 102: 4384-4392.
29. Kircheis R, Ostermann E, Wolschek MF, Lichtenberger C, Magin-Lachmann C, Wightman L et al. Tumor-targeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity. Cancer Gene Ther 2002; 9: 673-680.
30. Rasmussen H, Rasmussen C, Lempicki M, Durham R, Brough D, King CR et al. TNFerade biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 2002; 9: 951-957.
31. Marr RA, Addison CL, Snider D, Muller WJ, Gauldie J, Graham FL. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha. Gene Ther 1997; 4: 1181-1188.
32. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993; 177: 925-935.
33. Graf D, Muller S, Korthauer U, van Kooten C, Weise C, Kroczek RA. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 1995; 25: 1749-1754.
34. Peitsch MC, Jongeneel CV. A 3-D model for the CD40 ligand predicts that it is a compact trimer similar to the tumor necrosis factors. Int Immunol 1993; 5: 233-238.
35. Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 2000; 50: 184-195.
36. Paleolog EM, Delasalle SA, Buurman WA, Feldmann M. Functional activities of receptors for tumor necrosis factoralpha on human vascular endothelial cells. Blood 1994; 84: 2578-2590.
37. Stoelcker B, Ruhland B, Hehlgans T, Bluethmann H, Luther T, Mannel DN. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am J Pathol 2000; 156: 1171-1176.
38. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811.
39. Zimmermann VS, Bondanza A, Monno A, Rovere-Querini P, Corti A, Manfredi AA. TNF-alpha coupled to membrane of apoptotic cells favors the cross-priming to melanoma antigens. J Immunol 2004; 172: 2643-2650.
40. Huebner RJ, Rowe WP, Schatten WE, Smith RR, Thomas LB. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956; 9: 1211-1218.
41. Myers AL, Krewet JA, Shah MR. Tumor immunity and prolonged survival following combined adenovirus-HSP72 and CEA-plasmid vaccination. Vaccine 2005; 23: 3565-3571.
42. Shimomura K, Manda T, Mukumoto S, Kobayashi K, Nakano K, Mori J. Recombinant human tumor necrosis factor-alpha: thrombus formation is a cause of anti-tumor activity. Int J Cancer 1988; 41: 243-247.
43. Watanabe N, Niitsu Y, Umeno H, Kuriyama H, Neda H, Yamauchi N et al. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 1988; 48: 2179-2183.